Our platform uses AI to continuously analyze regional bacterial genome data, identifying which phages are best candidates for therapeutic use. These selected phages are pre-manufactured and securely stored in local and partner biobanks, ensuring they are ready to be delivered when time is critical.

Currently, we have access to over 4’000 unique phages through global partnerships.